調査レポートカテゴリー： Infiniti Research TechNavio, 北米, 医療/バイオ

HER-2 Positive Breast Cancer Market in the US 2015-2019

米国のHER2陽性乳がん治療市場2015-2019

◆タイトル：HER-2 Positive Breast Cancer Market in the US 2015-2019
◆商品コード：IRTNTR5344
◆調査・発行会社：Technavio (Infiniti Research Ltd.)
◆発行日：2015年3月18日
◆ページ数：108
◆資料形式：pdf / 英語
◆納品方法：Eメール
◆調査対象地域：米国
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）

Single User	USD3,000 ⇒換算￥339,000	見積依頼/購入/質問フォーム
Five User	USD3,500 ⇒換算￥395,500	見積依頼/購入/質問フォーム
Enterprise License（全社内共有可）	USD4,500 ⇒換算￥508,500	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、米国のHER2陽性乳がん治療市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、米国のHER2陽性乳がん治療市場規模及び予測、種類別分析、投与経路（ROA）別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。

About HER-2 Positive Breast Cancer
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio’s analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the HER-2 Positive Breast Cancer market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutics and chemotherapeutics used in the management of HER-2 positive breast cancer patients.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the HER-2 Positive Breast Cancer market in the US. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, HER-2 Positive Breast Cancer Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the HER-2 Positive Breast Cancer market in the US and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Vendors]
• Celgene
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Sanofi

[Other Prominent Vendors]
• Bristol-Myers Squibb
• DARA BioSciences
• Eisai
• Hospira
• Pfizer
• ProStrakan
• Sun Pharmaceutical Industries
• Teva Pharmaceutical

[Market Driver]
• Increase in Population of Breast Cancer Patients
• For a full, detailed list, view our report

[Market Challenge]
• Poor Diagnosis and Screening
• For a full, detailed list, view our report

[Market Trend]
• Increase in Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.4.1 IHC
06.4.2 FISH
06.4.3 SPoT-Light HER-2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
06.4.4 Inform HER-2 Dual ISH Test (Inform Dual In Situ Hybridization)
06.5 Management
06.5.1 Surgery
06.5.2 Radiotherapy
06.5.3 Chemotherapy
06.5.4 Targeted Therapy
06.5.5 Hormonal Therapy
06.6 Economic Burden

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Market Segmentation by Type of Therapy
08.1 Chemotherapy
08.1.1 Alkylating Agents
08.1.2 Antimetabolites
08.1.3 Cytotoxic Antibiotics
08.1.4 Taxanes
08.2 Targeted Therapy
08.3 Hormone Therapy

09.9 Market Segmentation by Molecule Type
09.1 Biologics
09.2 Small Molecules

10 Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral

11 Buying Criteria

12 Market Growth Drivers

13 Drivers and their Impact

14 Market Challenges

15 Impact of Drivers and Challenges

16 Market Trends

17 Trends and their Impact

18 Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Competitive Assessment of the Top Drugs
18.2.2 Celgene
18.2.3 F. Hoffmann-La Roche
18.2.4 GlaxoSmithKline
18.2.5 Novartis
18.2.6 Sanofi
18.3 Other Prominent Vendors

19 Key Vendor Analysis
19.1 Celgene
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Business Segmentation by Revenue
19.1.5 Sales by Geography
19.1.6 Key Information
19.1.7 SWOT Analysis
19.2 F. Hoffmann-La Roche
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.3 GlaxoSmithKline
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Pipeline Products
19.3.7 Business Strategy
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Novartis
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Revenue by Business Segmentation
19.4.5 Revenue Comparison 2012 and 2013
19.4.6 Sales by Geography
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis
19.5 Sanofi
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison 2012 and 2013
19.5.6 Sales by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis

20 Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Pathophysiology of HER-2 Positive Breast Cancer
Exhibit 3: Prevalence of HER-2 Positive Breast Cancer in US 2014
Exhibit 4: Prevalence of HER-2 Positive Breast Cancer in US 2014 (in percentage)
Exhibit 5: IHC: Diagnosis of HER-2 Positive Breast Cancer
Exhibit 6: FISH: Diagnosis of HER-2 Positive Breast Cancer
Exhibit 7: Management of HER-2 Positive Breast Cancer
Exhibit 8: ASCO Treatment Guidelines for HER-2 Positive Breast Cancer
Exhibit 9: Snapshot of Economic Burden of HER-2 Positive Breast Cancer Market in US
Exhibit 10: Snapshot of HER-2 Positive Breast Cancer Market in US 2014
Exhibit 11: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
Exhibit 12: Drivers and Challenges of HER-2 Positive Breast Cancer Market in US
Exhibit 13: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy
Exhibit 14: Segmentation of HER-2 Positive Breast Cancer Market in US by Type of Therapy 2014
Exhibit 15: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type
Exhibit 16: Segmentation of HER-2 Positive Breast Cancer Market in US by Molecule Type 2014
Exhibit 17: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration
Exhibit 18: Segmentation of HER-2 Positive Breast Cancer Market in US by Route of Administration 2014
Exhibit 19: Buying Criteria of HER-2 Positive Breast Cancer Market in US
Exhibit 20: Drivers and their Impact on Key Customer Category of HER-2 Positive Breast Cancer Market in US
Exhibit 21: Five-year Survival Rate by Stage of Diagnosis (SEER Analysis for 2004-2010)
Exhibit 22: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer 2013 (US$ million)
Exhibit 23: Celgene: Product Portfolio
Exhibit 24: Abraxane: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
Exhibit 25: F. Hoffmann-La Roche: Product Portfolio
Exhibit 26: Herceptin: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 27: Perjeta: Revenue 2012 and 2013 (US$ million)
Exhibit 28: Xeloda: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 29: GlaxoSmithKline: Product Portfolio
Exhibit 30: Tykerb: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 31: Novartis: Product Portfolio
Exhibit 32: Femara: YoY Growth Rate and Revenue 2010-2013 (US$ million)
Exhibit 33: Sanofi: Product Portfolio
Exhibit 34: Taxotere: YoY Growth Rate and Global Revenue 2010-2013 (US$ million)
Exhibit 35: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 36: Celgene: Sales by Geography 2013
Exhibit 37: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 38: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 40: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 41: GlaxoSmithKline: Business Segmentation 2013
Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 43: GlaxoSmithKline: Sales by Geography 2013
Exhibit 44: GlaxoSmithKline: Pipeline Products 2013
Exhibit 45: Novartis AG: Business Segmentation
Exhibit 46: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 47: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 48: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 49: Sanofi SA: Business Segmentation
Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013

【掲載企業】

Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi, Bristol-Myers Squibb , DARA BioSciences, Eisai , Hospira , Pfizer , ProStrakan, Sun Pharmaceutical Industries , Teva Pharmaceutical

【資料のキーワード】

米国、HER2陽性乳がん、治療、化学療法、治療薬

★調査レポート[米国のHER2陽性乳がん治療市場2015-2019] (HER-2 Positive Breast Cancer Market in the US 2015-2019 / IRTNTR5344)販売に関する免責事項

[米国のHER2陽性乳がん治療市場2015-2019] (HER-2 Positive Breast Cancer Market in the US 2015-2019 / IRTNTR5344)についてEメールでお問い合わせ

◆H&Iグローバルリサーチ株式会社のお客様（例）◆